Cargando…
Induction of retinol-binding protein 4 and placenta-specific 8 expression in human prostate cancer cells remaining in bone following osteolytic tumor growth inhibition by osteoprotegerin
New drugs that inhibit the osteoprotegerin (OPG)/receptor activator of NF-κB ligand (RANKL)/RANK pathway have demonstrated efficacy for the treatment of bone metastasis. Toxicities induced by these drugs, however, including osteonecrosis of the jaw and hypocalcemia, may adversely affect therapy. The...
Autores principales: | UEHARA, HISANORI, TAKAHASHI, TETSUYUKI, IZUMI, KEISUKE |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3775580/ https://www.ncbi.nlm.nih.gov/pubmed/23708710 http://dx.doi.org/10.3892/ijo.2013.1954 |
Ejemplares similares
-
Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts
por: Shiirevnyamba, A, et al.
Publicado: (2011) -
Inhibition of EP2/EP4 signaling abrogates IGF-1R-mediated cancer cell growth: Involvement of protein kinase C-θ activation
por: Takahashi, Tetsuyuki, et al.
Publicado: (2014) -
Expression of Osteoprotegerin in Placenta and Its Association with Preeclampsia
por: Shen, Pei, et al.
Publicado: (2012) -
Arming a Replicating Adenovirus with Osteoprotegerin Reduces the Tumor Burden in a Murine Model of Osteolytic Bone Metastases of Breast Cancer
por: Cody, James J., et al.
Publicado: (2010) -
High Susceptibility to Zymbal Gland and Intestinal Carcinogenesis in Diabetic
Otsuka Long-Evans Tokushima Fatty Rats
por: Hafez, Ezar, et al.
Publicado: (2011)